Navigation Links
Stimatix GI Reports Encouraging Interim Results
Date:5/3/2010

MISGAV, Israel, May 3, 2010 /PRNewswire/ --

- The Company is Developing an Artificial Sphincter (the AOS-C1000) to Provide Bowel Control and Prevent Clinical Complications for People With Stomas.

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

The interim results demonstrate that the AOS-C1000 artificial sphincter can restore voluntary control to people with stoma.

A stoma is the result of a surgical procedure that diverts the end of the bowel to an artificial opening ("stoma") in the abdominal wall. Bowel content and intestinal gases exit through the stoma. People with stoma lose the ability to control elimination and the contents of the bowel spill out uncontrollably. Consequently, a collection bag is always attached to the stoma.

There are many side-effects of using such a bag, including a significant change in lifestyle, an impact on self-image, problems reintegrating into society, unpleasant odors, leaks, and intrusive bowel noises. Additional clinical complications may arise in the long term, including severe skin rashes around the stoma and parastomal hernia.

Stimatix's artificial sphincter, the AOS-C1000, restores patients' control over the human elimination function. The sphincter is installed in a simple procedure during the creation of the stoma (or in a separate surgical procedure for those who already have a stoma).

The artificial sphincter, discreet and aesthetic, can significantly improve quality of life of stoma patients, while greatly reducing potential clinical complications.

According to David Hanuka, CEO of Stimatix GI, "The AOS-C1000 has the potential to improve the lives of stoma patients. Despite vast resources that have been invested over the last 50 years, no complete solution is available for patients whose quality of life and self-image are impaired. The interim results of the trial encourage us to continue developing the device to achieve the desired breakthrough."

About Stimatix GI

Stimatix GI (http://www.stimatix-gi.com) is a life-science startup that is developing an innovative artificial sphincter for stoma patients.

The current state of the art is based on techniques devised during the last 50 years which rely on an external pouch that collects bowel contents.

The current annual world market for stoma pouches is estimated at $2 billion.

    Stimatix GI seeks to improve quality of life with the AOS-C1000 for
people with stoma.
    Contact:

    David Hanuka, CEO
    Stimatix GI Ltd.
    T +972-72-260-7084
    info@stimatix-gi.com



'/>"/>
SOURCE Stimatix GI Ltd
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
2. Repligen Reports Notice of Allowance of a United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder
3. Capstone Reports Additional High Grade Copper-Gold Results From Minto East
4. Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent Developments
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results
6. Sequenom Reports 2009 Fourth Quarter and Full Year Financial Results
7. APC Group, Inc. Reports Fiscal Year End Sales Revenues Increased 30% for 2009
8. NOVAVAX Reports Fourth Quarter and 2009 Year-End Financial Results
9. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
10. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):